Correlation of Long Noncoding RNA SEMA6A-AS1 Expression with Clinical Outcome in HBV-Related Hepatocellular Carcinoma

Yu, Songman; Li, Ning; Wang, Juan; Fu, Yukui; Huang, Yan; Yi, Panpan; Chen, Ruochan; Tang, Daolin; Hu, Xingwang; Fan, Xue‐Gong

doi:10.1016/j.clinthera.2020.01.012

Cited by 14 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, SEMA6A-AS1 expression in HBV-related HCC tissues was significantly downregulated compared with that in paracancerous tissues. Furthermore, low levels of SEMA6A-AS1 were associated with high α -fetoprotein levels, high stage of lymph node metastasis, and poor clinical response [ 34 ]. Both the Kaplan–Meier survival analysis method and the univariate Cox proportional hazards regression model showed that low expression of SEMA6A-AS1 was correlated with an overall poor survival rate.…”

Section: Discussionmentioning

confidence: 99%

Immune-Related lncRNAs with WGCNA Identified the Function of SNHG10 in HBV-Related Hepatocellular Carcinoma

Hou

Wang

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Objective. The hepatitis B virus (HBV) infection led to hepatitis, which was one of common reasons for hepatocellular carcinoma (HCC). The immune microenvironment alteration played a crucial role in this process. The study aimed to identify immune-related long noncoding RNAs (lncRNAs) in HBV-related HCC and explore potential mechanisms. Methods. In total, 1,072 immune‐related genes (IRGs) were enriched in different co-expression modules with weighted gene co-expression network analysis (WGCNA) combining the corresponding clinical features in HBV-related HCC. The immune-related lncRNAs were selected from the crucial co-expression model based on the correlation analysis with IRGs. The immune-related lncRNAs were furtherly used to construct prognostic signature by the Cox proportional hazards regression and Lasso regression. Furthermore, the proliferation and migration ability of lncRNA SNHG10 were verified in vitro. Results. A total of nine co-expression modules were identified by WGCNA of which the “red” co-expression module was most correlated with various clinical characteristics. Additionally, the IRGs in this module were significantly enriched in multiple immune-related pathways. The twelve immune-related lncRNAs prognostic signature (HAND2-AS1, LINC00844, SNHG10, MALAT1, LINC00460, LBX2-AS1, MIR31HG, SEMA6A-AS1, LINC1278, LINC00514, CTBP-AS2, and LINC00205) was constructed. The risk score was an independent risk factor in HBV-related HCC and verified by principal components analysis (PCA), nomogram, and PCR between different cell lines. Moreover, the proportion of immune cells were significantly different between high-risk score group and low-risk score group. The malignant behavior of Hep3B was significantly different between si-lncRNA SNHG10 and control group. Conclusions. The immune-related lncRNAs prognostic signature provided some potential biomarkers and molecular mechanisms in HBV-related HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune-Related lncRNAs with WGCNA Identified the Function of SNHG10 in HBV-Related Hepatocellular Carcinoma

Hou

Wang

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…In this study, we first established a novel model with lncRNAs signature to predict melanoma prognosis. In this model, several sIRlncRs had been found to play an important role in the malignant phenotypes of various cancer types, such as AC022509.2, 30 LINC02544, 33 AC091057.1, 34 HLA-DQB1-AS1, 34 SEMA6A-AS1, 35 AL365361.1, 36 , 37 and UBA6-AS1. 38 For example, UBA6-AS1 promoted GBM’s malignant progression by targeting the miR-760/HOXA2 axis.…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of Immune-Related lncRNA Signature as a Prognostic Model for Skin Cutaneous Melanoma

Shuai¹,

Wang²,

He³

et al. 2021

PGPM

View full text Add to dashboard Cite

Purpose Skin cutaneous melanoma (SKCM) is the most aggressive skin cancer that results in high morbidity and mortality rate worldwide. Immune-related long non-coding RNAs (IRlncRs) play an important role in regulating gene expression in tumors. Therefore, in this study, we aimed to identify IRlncRs signature that could predict prognosis and therapeutic targets for melanoma irrespective of the gene expression levels. Methods RNA-sequencing data were obtained from The Cancer Genome Atlas (TCGA). IRlncRs were identified using co-expression analysis and recognized using univariate analysis. The impact of IRlncRs on survival was analyzed using a modified least absolute shrinkage and selection operator (Lasso) regression model. A 1-year survival receiver operating characteristic curve was constructed, and the area under the curve was calculated to identify the optimal cut-off point to distinguish between high and low-risk groups in patients with SKCM. Furthermore, integrative analysis was performed to identify the impact of clinicopathological features, chemotherapeutic treatment, tumor-infiltrating immune cells, and mutant genes on survival. Results A total of 28 IRlncRs significantly associated with survival were identified. Seventeen IRlncRs pairs were used to build a survival risk model that could be used to distinguish between low and high-risk groups. The high-risk group was negatively associated with tumor-infiltrating immune cells and had a higher half inhibitory centration for chemotherapeutic agents such as cisplatin and vinblastine. Additionally, the high-risk group had a positive correlation with the expression of specific mutant genes such as BRAF and KIT. Conclusion Our findings demonstrate that some IRlncRs have a significant correlation with survival and therapeutic targets for SKCM patients and may provide new insight into the clinical diagnosis and treatment strategies for SKCM patients.

show abstract

“…SEMA6A-AS1 is a newly discovered antisense RNA of downregulated signaling protein 6 in L02/HBx cell lines. Yu et al (2020) showed for the first time that a decrease in SEMA6A-AS1 expression is positively correlated with OS in HBV-related liver cancer. Decreased expression of SEMA6A-AS1 is associated with a poor prognosis in patients with HBVrelated HCC.…”

Section: Sema6a-as1mentioning

confidence: 93%

Current State and Progress of Research on the Role of lncRNA in HBV-Related Liver Cancer

Wang

Kang

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a malignant tumor with the highest mortality rate in the world, and hepatitis B virus (HBV) plays an important role in its development. Long noncoding RNA (lncRNA) is highly related to the inactivation of tumor suppressor genes and the activation of oncogenes in HCC. Researchers have used high-throughput sequencing technology to identify many noncoding transcripts related to the development of HCC and have studied the interaction between these transcripts and DNA, RNA, or protein to determine the relevant mechanism in the development of HCC. In general, the research on lncRNA represents a new field of cancer research, and the imbalance in lncRNA plays an pivotal role in the occurrence of liver cancer. In this review, we summarize some of the dysfunctional lncRNAs in human HCC associated with HBV infection. Their regulatory pathways, functions, and potential molecular mechanisms in the occurrence and development of HCC are discussed.

show abstract

Correlation of Long Noncoding RNA SEMA6A-AS1 Expression with Clinical Outcome in HBV-Related Hepatocellular Carcinoma

Cited by 14 publications

References 33 publications

Immune-Related lncRNAs with WGCNA Identified the Function of SNHG10 in HBV-Related Hepatocellular Carcinoma

Immune-Related lncRNAs with WGCNA Identified the Function of SNHG10 in HBV-Related Hepatocellular Carcinoma

Identification and Validation of Immune-Related lncRNA Signature as a Prognostic Model for Skin Cutaneous Melanoma

Current State and Progress of Research on the Role of lncRNA in HBV-Related Liver Cancer

Contact Info

Product

Resources

About